30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Reimbursement / Regulatory

Vericel plans to submit a Biologics License Application to FDA by the end of 2015 for MACI™ (matrix-applied characterized autologous cultured chondrocytes) for the treatment of focal chondral knee cartilage defects. MACI is a 3rd-generation autologous chondrocyte implantation product. (Vericel Corporation, 6/10/15)